Checkpoint Therapeutics, Inc. - Common Stock (CKPT)
3.7300
+0.3400 (10.03%)
Checkpoint Therapeutics Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative treatments for cancer
The company specializes in targeted and immune-oncology therapies, aiming to advance new options for patients suffering from various types of solid tumors. Through its research initiatives and clinical trials, Checkpoint Therapeutics seeks to develop therapies that can effectively address unmet medical needs in oncology, leveraging modern scientific advancements to enhance patient outcomes.
Checkpoint Therapeutics' Unloxcyt wins FDA approval for advanced cSCC, marking the company's entry into the U.S. market, valued over $1 billion annually.
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Checkpoint Therapeutics, Inc. (NASDAQCKPT) on behalf of long-term stockholders following a class action complaint that was filed against Checkpoint on April 5, 2024 with a Class Period from March 10, 2021 to December 15, 2023. Our investigation concerns whether the board of directors of Checkpoint have breached their fiduciary duties to the company.
WHY: NEW YORK, NY - (NewMediaWire) - June 4, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Checkpoint Therapeutics, Inc. (NASDAQCKPT) between March 10, 2021 and December 15, 2023, both dates inclusive (the “Class Period”), of the important June 4, 2024 lead plaintiff deadline.
LOS ANGELES, June 04, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Checkpoint Therapeutics, Inc. (“Checkpoint” or “the Company”) (NASDAQCKPT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The Law Offices of Frank R. Cruz reminds investors of the upcoming June 4, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQCKPT) securities between March 10, 2021 and December 15, 2023, inclusive (the “Class Period”).
WHY: NEW YORK, NY - (NewMediaWire) - June 3, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Checkpoint Therapeutics, Inc. (NASDAQCKPT) between March 10, 2021 and December 15, 2023, both dates inclusive (the “Class Period”), of the important June 4, 2024 lead plaintiff deadline.
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQCKPT) and reminds investors of the June 4, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQCKPT) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Checkpoint securities between March 10, 2021 and December 15, 2023, both dates inclusive (the “Class Period”). Investors have until June 4, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQCKPT) and reminds investors of the June 4, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
LOS ANGELES, May 28, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Checkpoint Therapeutics, Inc. (“Checkpoint” or “the Company”) (NASDAQCKPT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
WHY: NEW YORK, NY - (NewMediaWire) - May 26, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Checkpoint Therapeutics, Inc. (NASDAQCKPT) between March 10, 2021 and December 15, 2023, both dates inclusive (the “Class Period”), of the important June 4, 2024 lead plaintiff deadline.
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQCKPT) and reminds investors of the June 4, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Checkpoint Therapeutics, Inc. (NASDAQCKPT) securities between March 10, 2021 and December 15, 2023. Checkpoint is a clinical-stage immunotherapy and targeted oncology company that focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the U.S. and internationally.
LOS ANGELES, May 21, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Checkpoint Therapeutics, Inc. (“Checkpoint” or “the Company”) (NASDAQCKPT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
